Results
Retatrutide Reported Results
Efficacy and tolerability endpoints as reported in trial publications and sponsor disclosures. Figures currently shown are demonstration data pending verification.
Efficacy
Latest Retatrutide Data
Headline figures from the most advanced reported dataset, presented for orientation only.
Latest Efficacy Result
Data connection pending
Awaiting verified endpoint data from sponsor topline reports
Trial
TRIUMPH-1
Adults with obesity, no type 2 diabetes
Study Duration
72 weeks
Randomised, double-blind treatment period
Participants
2,140
Randomised across all treatment arms
Dose
12 mg weekly
Highest maintenance dose reported
Source
Sponsor topline
Illustrative summary — demo data
Sample figures shown for layout purposes. Verified values, confidence intervals and source citations will be published per trial and per endpoint.
Preview Tool
Retatrutide Results Explorer
Filter reported efficacy and tolerability endpoints by trial, dose and treatment duration. Selections are illustrative in this preview.
Mean Weight Change
All values are demonstration data used to prototype the explorer interface. Verified endpoint data, analysis populations and citations will replace them.
Weekly Briefing
The Retatrutide Report
One concise briefing covering the most important retatrutide clinical trial, research and regulatory developments.
No promotional content. Unsubscribe at any time.